Stents

This channel includes news and new technology innovations for stents, also called vascular scaffolds. Stents are used to help prop open a vessel treated by balloon angioplasty because of the barotrauma caused by the extreme stretching of vessel walls. The stent enables to vessel to heal in an open position with collapsing. Drug eluting stents (DES) are coated in anti-proliferative drugs to precent scar tissue growth which can cause restenosis and occlude the vessel. DES require antiplatelet therapy because the drug carrier polymer on DES can cause thrombus inside the stent, even years after treatment, which is why bare metal stents are still used in some patients. This page includes news on coronary stents, carotid stents, peripheral stents, bioresorbable stents, and renal stents.

A peripheral artery disease (PAD) patient CT scan showing blockages in the femoral arteries in the legs with collateral flow in the leg on the right.

News | Stents Bioresorbable

First-In-Human Use Reported for Bioresorbable Efemoral Vascular Scaffold System

December 16, 2020 — Efemoral Medical announced the first-in-human (FIH) use of the its Efemoral bioresorbable vascular ...

December 16, 2020

One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT drug-eluting stent (DES), to the Xience or Promus Durable Polymer DES showed it was equivalent in clinical performance to the market-leading DES. The results were presented at the 2020 American Heart Association (AHA) Scientific Session. #AHA2020 #AHA20 #AHA

News | Stents

Biodegradable Drug Eluting Coronary Stent Noninferior to Xience or Promus Durable Polymer Stents

November 24, 2020 — One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT ...

November 24, 2020

Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip. Acurate neo TAVR valve. #TCTconnect #TCT2020

Feature | TCT | Dave Fornell, Editor

Top 10 Takeaways on Interventional Technologies at TCT 2020

Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials ...

October 29, 2020

Abre venous self-expanding stent found safe, effective in treating challenging deep venous lesions was approved by the FDA.

News | Venous Therapies

Medtronic Venous Stent Receives U.S. FDA Approval to Treat Venous Outflow Obstruction

October 26, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the Medtronic Abre venous self-expanding ...

October 26, 2020

Ori Ben-Yehuda, M.D., presenting the findings of the HOST-REDUCE-POLYTECH-ACS study at TCT 2020 that showed durable polymer drug-eluting stents (DES) performed better than the bioresorbable polymer DES that were supposed to replace them with the promise of being safer and lowering overall cardiac event rates. #TCT2020 #TCTConnect

Feature | Stents | Dave Fornell, Editor

Durable Polymer Drug-Eluting Stents Perform Better Than Biodegradable Polymer DES

October 17, 2020 – In a surprise to many, a randomized clinical trial found that drug-eluting stents (DES) with durable ...

October 22, 2020

For patients undergoing percutaneous coronary intervention (PCI), treatment with the CeloNova Biosciences nanotechnology polymer-coated Cobra PzF stent plus 14-day dual anti-platelet therapy (DAPT) did not reduce bleeding or establish non-inferior outcomes for thrombotic events compared with a drug-eluting stent (DES) and standard three or six-month DAPT therapy. #TCT #TCTconnect #TCT2020

News | Stents

Nano-Coated Coronary Stent and Shorter DAPT Did Not Meet Non-inferiority for Thrombotic Events

October 22, 2020 – For patients undergoing percutaneous coronary intervention (PCI), treatment with the nanotechnology ...

October 22, 2020

Videos | Stents Drug Eluting

VIDEO: Results of the OPTIMIZE IDE Trial for the Svelte Drug Eluting Stent

Dean Kereiakes, M.D., medical director, The Christ Hospital Heart and Vascular Center, medical director, The Christ ...

October 19, 2020

Videos | Antiplatelet and Anticoagulation Therapies

VIDEO: Use of Shorten DAPT and the Xience Stent in High-bleeding Risk Patients

Roxana Mehran, M.D., and Marco Valgimiggle, M.D., present the results of the Xience 90/28 trials that evaluated the use ...

October 19, 2020

A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect

Feature | Cath Lab

No Mortality Risk Associated With Paclitaxel-coated Devices Used to Treat Peripheral Artery Disease

October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benefit ...

October 18, 2020

Videos | Cath Lab

VIDEO: Pre-emptive Treatment of Vulnerable Plaques With Bioresorbable Stents

Gregg Stone, M.D., presents the results of the PROSPECT ABSORB Trial in a press conference at the 2020 ranscatheter ...

October 17, 2020

The Abbott Vascular Xience Sierra drug eluting stent (DES). The XIENCE 28 and XIENCE 90 studies presented at TCT 2020 showed the stent can be used safely with only one month of dual antiplatelet therapy (DAPT). #TCT #TCTconnect #TCT2020

News | Stents Drug Eluting

Shorter DAPT With Xience Stent is Noninferior to Standard DAPT

October 16, 2020 – Results from the XIENCE 90/28 clinical trials have shown that a shorter course of dual-antiplatelet ...

October 16, 2020

The FDA has cleared a new indication for the Medtronic Resolute Onyx Drug Eluting Stent, making it the first DES that only required one month of dual antiplatelet therapy (DAPT) in patients who are considered high risk for bleeding complications.

News | Stents

Medtronic Resolute Onyx Drug Eluting Stent First to Receive One-Month DAPT Indication

October 1, 2020 — Medtronic has received U.S. Food and Drug Administration (FDA) approval for new one-month of dual ...

October 01, 2020

The Opimax TiNO bio-active coated stent made by Hexacath.

News

Optimax Nitride-oxide Coated Stent Superior to Synergy Drug-eluting Stent in TIDES-ACS Trial

September 5, 2020 – The TIDES-ACS Randomized Controlled Trial results were published end of July 2020 confirming the ...

September 10, 2020

The U.S. Centers for Medicare and Medicaid Services (CMS) granted a New Technology Add-on Payment (NTAP) for the Boston Scientific Eluvia Drug-Eluting Vascular Stent System as part of the 2021 Inpatient Prospective Payment System (IPPS).

News | Peripheral Artery Disease (PAD)

CMS Grants Additional Reimbursement for Eluvia Vascular Stent

September 4, 2020 — The U.S. Centers for Medicare and Medicaid Services (CMS) granted a New Technology Add-on Payment ...

September 04, 2020

Abbott Espirit BTK Bioresorbable stent, or bioresorbable vascular scaffold (BVS) measures 99 microns and is made from poly-L-lactide (PLLA), a semi-crystalline bioresorbable polymer engineered to resist vessel recoil and provide a platform for drug delivery. Abbott Absorb

Feature | Stents Bioresorbable

Abbott Restarts Bioresorbable Stent Clinical Trials With New Esprit Below-the-knee Scaffold

September 3, 2020 — Abbott today announced the start of the LIFE-BTK clinical trial to evaluate the safety and ...

September 03, 2020